We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$988M
AUM Growth
-$31.3M
Cap. Flow
-$56.5M
Cap. Flow %
-5.72%
Top 10 Hldgs %
45.25%
Holding
164
New
47
Increased
25
Reduced
25
Closed
38

Top Buys

Rank Stock Value
1
OTIC
Otonomy, Inc.
OTIC
+$16.6M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$11.4M
3
ARWR icon
Arrowhead Research
ARWR
+$11.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.4M
5
EPZM
Epizyme, Inc
EPZM
+$7.5M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$37M
2
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$24.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.9M
4
SHPG
Shire pic
SHPG
+$21.2M
5
INSM icon
Insmed
INSM
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.83%
2 Financials 0.18%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
26
DELISTED
Aravive, Inc. Common Stock
ARAV
$9.25M 0.94%
81,210
+28,577
+54% +$3.79M
NEPT
27
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$9.07M 0.92%
4,786
– –
AGN
28
DELISTED
Allergan Inc
AGN
$8.91M 0.9%
50,000
– –
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$8.73M 0.88%
610,000
-190,000
-24% -$2.73M
SGMO
30
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.63M 0.87%
800,000
– –
ARCT icon
31
CALL
Arcturus Therapeutics
ARCT
$165M
$8.29M 0.84%
+76,714
New +$10M
INSM icon
32
Insmed
INSM
$22.4B
$7.83M 0.79%
600,000
-1,200,000
-67% -$18.1M
EPZM
33
DELISTED
Epizyme, Inc
EPZM
$7.7M 0.78%
283,890
+241,288
+566% +$7.5M
ARCT icon
34
PUT
Arcturus Therapeutics
ARCT
$165M
$7.52M 0.76%
+69,571
New +$9.07M
HRTX icon
35
Heron Therapeutics
HRTX
$93.4M
$7.38M 0.75%
885,352
-749,203
-46% -$6.98M
VNDA icon
36
PUT
Vanda Pharmaceuticals
VNDA
$304M
$7.27M 0.74%
+700,000
New +$9.18M
PRTA icon
37
Prothena Corp
PRTA
$448M
$6.65M 0.67%
300,000
-183,162
-38% -$3.88M
SAGE
38
DELISTED
Sage Therapeutics
SAGE
$6.57M 0.67%
+208,676
New +$6.05M
LCI
39
DELISTED
Lannett Company, Inc.
LCI
$6.15M 0.62%
+33,642
New +$5.39M
ASXC
40
DELISTED
Asensus Surgical, Inc.
ASXC
$5.72M 0.58%
100,919
+919
+0.9% +$49.5K
AGTC
41
DELISTED
Applied Genetic Technologies Corporation
AGTC
$5.53M 0.56%
296,978
+150,000
+102% +$2.72M
AVNR
42
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$5.48M 0.56%
+460,000
New +$3.14M
AERI
43
DELISTED
Aerie Pharmaceuticals
AERI
$5.44M 0.55%
1,121,951
– –
LRMR icon
44
Larimar Therapeutics
LRMR
$377M
$5.4M 0.55%
+22,917
New +$5.19M
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.23M 0.53%
306,000
-394,000
-56% -$5.72M
TRVN
46
DELISTED
Trevena, Inc.
TRVN
$4.94M 0.5%
1,232
– –
PCYC
47
DELISTED
PHARMACYCLICS INC
PCYC
$4.7M 0.48%
+40,000
New +$4.56M
MGNX icon
48
MacroGenics
MGNX
$233M
$4.47M 0.45%
213,703
-218,100
-51% -$4.51M
THC icon
49
Tenet Healthcare
THC
$22.2B
$4.01M 0.41%
+67,500
New +$3.77M
THOR
50
DELISTED
THORATEC CORPORATION
THOR
$3.94M 0.4%
+147,501
New +$4.19M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Perceptive Advisors held 164 positions worth $988M, down 3.1% from $1.02B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $56.5M in Q3 2014, closing 38 positions and reducing 25 holdings. Its most notable exit was QUESTCOR PHARMA INC, an estimated $37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Otonomy, Inc. worth $20.1M.

  • Perceptive Advisors's largest Q3 2014 buy was Otonomy, Inc.: 837,400 shares worth $20.1M.
  • Perceptive Advisors added most to Arrowhead Research in Q3 2014, an estimated $11.3M increase.
  • Perceptive Advisors's biggest Q3 2014 reduction was Taro Pharmaceutical Industries Ltd., cutting an estimated $24.1M.
  • Perceptive Advisors fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $37M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $988M portfolio in Q3 2014.
  • Perceptive Advisors opened 47 new positions and closed 38 in Q3 2014.
  • Perceptive Advisors's portfolio value fell 3.1% quarter-over-quarter to $988M.

Based on Perceptive Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.